Hikma Pharmaceuticals Share News (HIK)

BROKER RATINGS SUMMARY: JPMorgan Raises Auto Trader To Overweight

AGM, EGM Calendar - Week Ahead

BROKER RATINGS SUMMARY: Panmure Gordon Raises DCC To Buy After Update

FTSE 100 movers: Housebuilders lead market higher

(ShareCast News) - The FTSE 100 was set to turn things around on Wednesday, with the blue chip market up 48.39 points (0.86%) to 5,680.58 by mid-afternoon. Housebuilders were on the rise, including Taylor Wimpey, Berkeley Group Holdings and Barratt Developments, after sector peer Bellway reported st

LONDON MARKET MIDDAY: Stocks Up As Investors Await Yellen's Testimony

UPDATE 3-Hikma cuts offer for Boehringer's U.S. generic drug unit

* Hikma agrees with Boehringer on lower price for Roxane * Cash component of initially $1.18 bln cut by $535 mln * Roxane's 2016 sales now seen below 2015 levels (Adds Boehringer statement, bullet points, rebates) By Noor Zainab Hussain and Esha Vaish Feb 10 (Reuters) -

WINNERS & LOSERS SUMMARY: Roxanne Labs Revenue Miss Hits Hikma Shares

LONDON MARKET OPEN: Shares Open Firm Even As Hikma And ARM Sink

LONDON BRIEFING: Hikma And ARM Shares Sold After Pre-Market Updates

Hikma Pharmaceuticals Agrees USD535 Million Price Cut For Roxane Deal

Hikma cuts cash consideration for Roxane by £370m

(ShareCast News) - Hikma Pharmaceutical's takeover of Roxane Laboratories took on a new shape on Wednesday, with the cash consideration being almost halved off the back of significantly lower revenue projections. The FTSE 100 company had published a prospectus on 22 January in relation to the acquis

LONDON MARKET OPEN: Hikma Up, Hargreaves Lansdown Down In Soft Open

FTSE 100 movers: BP leads market fallers on losses

(ShareCast News) - The FTSE 100 was back below 6,000 on Tuesday, dropping 151.22 points (2.5%) to 5,908.88 by mid-afternoon. BP took the biggest hit after $2.6bn of write-downs and restructuring charges sent it crashing into losses for the fourth quarter and full year. A $3.31bn loss was reported f

BUZZ-Hikma: top of the FTSE 100 on BAML upgrade

** Hikma rises 3 pct after BAML upgrades to "buy" from "neutral" ** Says it sees generous synergies from Roxane Laboratories acquisition; expects co to shut either its own or Roxane's US generics manufacturing plant ** Adds minimal colour on current pipeline but some large opportuniti

BROKER RATINGS SUMMARY: JPMorgan Cuts Merlin To Underweight